How Atsena Got Its Gene Therapy To Spread Subretinally To Treat XLRS

A conversation with Sanford Boye, co-founder and adviser, UF Startup Atsena Therapeutics.

Delivering AAV gene therapy to the retina to treat a rare inherited retinal disease is not without risk.

For one, using conventional gene therapy vectors to target genes to the central retina (the area where therapy is needed) requires detaching that region of the retina. Beyond that, transduction doesn’t happen much beyond the injection bleb, which can limit therapeutic effect.

Read more about How Atsena Got Its Gene Therapy To Spread Subretinally To Treat XLRS.